Effect of Hepatic Impairment on the Pharmacokinetics of Alectinib

Inclusion Criteria

All Participants

• Body mass index between 18 to 35 kilograms per square meter (kg/m^2) inclusive and weight greater than (>) 50 kilograms (kg)
• Female participants must be surgically sterile or post-menopausal
• Male participants and their partners of child-bearing potential must be willing to use 2 effective methods of contraception, one of which must be a barrier method

Participants with Hepatic Impairment

• Documented chronic stable liver disease (Child-Pugh Class A, B or C)

Exclusion Criteria

All Participants

• Pregnant or lactating women, males with female partners who are pregnant or lactating, or women of child bearing potential
• Positive test for drugs of abuse or alcohol
• Participation in an investigational drug or device study within 45 days or 5 half-lives (whichever time period is longer) or 6 months for biologic therapies prior to study drug administration
• History of hypersensitivity to any of the additives in the alectinib formulation
• Participants under judicial supervision, guardianship, or curatorship
• History of severe drug-related allergic reactions or drug-induced hepatotoxicity

Healthy Participants

• Use of any medications (prescription or over-the-counter), within 2 weeks or 5 half-lives (whichever longer) prior to study drug administration
• Use of any herbal supplements or any metabolic inducers within 4 weeks, or 5 half-lives (whichever is longer) prior to study drug administration

Participants with Hepatic Impairment

• Positive screening test for human immunodeficiency virus (HIV)
• History of liver transplantation
• Hepatocellular carcinoma or acute liver disease
• Severe ascites at screening or admission to the clinic
• Recent history (past 2 years) or current severe hepatic encephalopathy (Grade 3 or higher)
• Any evidence of progressive liver disease within the last 4 weeks
• Presence of surgically created or transjugular intrahepatic portal systemic shunts